Medtronic’s Cardiac Disease Management Offerings Seek To Grow HF Market
This article was originally published in The Gray Sheet
Executive Summary
Medtronic believes that its foray into cardiac disease management with the Chronicle implantable hemodynamic monitor will differentiate its devices from competitors Guidant and St. Jude
You may also be interested in...
FDA Panel To Review Medtronic’s Chronicle Heart Failure Monitor March 1
FDA's Circulatory System Devices Panel will consider Medtronic's PMA for the Chronicle continuous cardiac monitor for congestive heart failure patients at its March 1 meeting in Gaithersburg, Md
FDA Panel To Review Medtronic’s Chronicle Heart Failure Monitor March 1
FDA's Circulatory System Devices Panel will consider Medtronic's PMA for the Chronicle continuous cardiac monitor for congestive heart failure patients at its March 1 meeting in Gaithersburg, Md
Medtronic Begins Prospective Trial Of Chronicle Remote Monitoring ICD
Medtronic's next-generation implantable cardioverter defibrillator (ICD) is a hybrid of two of the company's previously developed technologies